Abstract:Background: The authors retrospectively analyzed 87 patients with malignant thymoma treated at M.D. Anderson Cancer Center between 1951 and 1990. The analysis examined the clinical stages, histologic types, and treatment modalities and attempted to determine if chemotherapy had an impact on survival. Methods: The patients were divided into three groups by their year of treatment and treatment modality. Patients treated between 1951 and 1975 were in Group I; patients treated between 1976 and 1980 were in Group II; and patients treated between 1981 and 1990 were in Group III. Most of the patients (18 [72%] in Group I; 16 [62%] in Group II; and 18 [50%] in Group III) had surgical resection alone or with radiotherapy. Patients with advanced-stage disease in Group I received single-agent chemotherapy, whereas patients with advanced-stage disease in Group II received a different, combination chemotherapy regimen, and those in Group III were treated primarily with cisplatin- and doxorubicin-based combination chemotherapy, e.g., the cyclophosphamide doxorubicin, and cisplatin with or without prednisone. The 17 patients treated with cisplatin with or without prednisone were separately evaluated for survival according to their response. Results: Twenty-eight patients (5 [20%] in Group I; 6 [23%] in Group II; and 17 [47%] in Group III) received chemotherapy alone or after surgery or radiotherapy. The cisplatin with or without prednisone regimen was used in 17 Group III patients for initial treatment or for relapse. The overall response rate among the patients receiving the cisplatin with or without prednisone regimen was 64%; 6 (35%) had a complete response, and 5 (29%) had a partial response. Thirty-one (36%) of the 87 total patients had 45 recurrent tumors; the lung (29%), pleura (22%), and mediastinum (18%) were the most common sites of recurrence, whereas bone was the most common distant metastatic site. The 5-year survival rate was 70% in patients with Stage I disease, 71% in patients with Stage II or III disease, and 46% in patients with Stage IV disease. The 10-year survival rate was 70% in patients with Stage I disease, 47% in patients with Stage II or III disease, and 21% in patients with Stage IV disease. Statistical analysis indicated a significant difference among the survival rates of patients with noninvasive Stage I, invasive Stage II plus III (P = 0.033), and Stage II plus III and IV tumors (P = 0.056), but not between patients with Stage II or III tumors. Patients with a major response to the cisplatin with or without prednisone regimen had a significant survival improvement compared to those with no response (P = 0.002, log-rank test). Conclusions: Because thymoma is a chemosensitive tumor and frequently recurs in patients with Stage II or greater disease, chemotherapy carries a potential survival benefit and should be incorporated into the multimodality approach to prolong disease-free survival.

Prolonged Survival Time with Surgical Therapy in Different Types of Thymoma: an Analysis Based on Surveillance Epidemiology and End Results Database.

Surgical treatment of thymoma: an 11-year experience with 761 patients.

Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database

Surgical Treatment of Invasive Thymoma: a Prognostic Retrospective Study

P01. Long-term survival after surgical treatment of thymic carcinoma

Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases.

Single-center evaluation of prognostic factors for thymoma treated by surgery: a retrospective study

The Role of Surgery in Advanced Thymic Tumors: A Retrospective Cohort Study

Thymoma Size Significantly Affects the Survival, Metastasis and Effectiveness of Adjuvant Therapies: a Population Based Study.

Stoical therapy and pathological analysis of thymoma

The long-term outcome and prognostic factors analysis of multimodality treatment for 283 patients with thymoma

Management and Long-Term Outcomes of Advanced Stage Thymoma in the United States

Surgery in Masaoka Stage IV Thymic Carcinoma: a Propensity-Matched Study Based on the SEER Database.

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Long-Term Survival in Thymic Epithelial Tumors: A Single-Center Experience from China

Thymic Squamous Cell Carcinoma: A Population-Based Surveillance, Epidemiology, and End Result Analysis

Risk factor analysis of thymoma resection and its value in guiding clinical treatment

[Thymoma-Report of 166 Patients].

Clinical analysis of postoperative radiotherapy in type B3 thymoma patients

Thymoma. A retrospective study of 87 cases

Clinical Outcomes and Prognosis of Recurrent Thymoma Management